Academic Journal
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
| العنوان: | Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs? |
|---|---|
| المؤلفون: | Busygina, Kristina, Denzinger, Viola, Bernlochner, Isabell, Weber, Christian, Lorenz, Reinhard, Siess, Wolfgang |
| المصدر: | Busygina , K , Denzinger , V , Bernlochner , I , Weber , C , Lorenz , R & Siess , W 2019 , ' Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs? ' , Thrombosis and Haemostasis , vol. 119 , no. 8 , pp. 1212-1221 . https://doi.org/10.1055/s-0039-1687877 |
| سنة النشر: | 2019 |
| المجموعة: | Maastricht University Research Publications |
| مصطلحات موضوعية: | ACALABRUTINIB ACP-196, BRUTONS TYROSINE KINASE, Btk inhibitor, CA2+ ENTRY, COMPLEMENTARY ROLES, GLYCOPROTEIN-VI, GPIb, GPVI, GPVI-FC, PLATELET THROMBUS FORMATION, SRC FAMILY, TERM-FOLLOW-UP, X-LINKED AGAMMAGLOBULINEMIA, bleeding, platelet, IBRUTINIB TREATMENT |
| الوصف: | Bruton's tyrosine kinase (Btk) is essential for B cell differentiation and proliferation, but also platelets express Btk. Patients with X-linked agammaglobulinemia due to hereditary Btk deficiency do not show bleeding, but a mild bleeding tendency is observed in high dose therapy of B-cell malignancies with ibrutinib and novel second-generation irreversible Btk inhibitors (acalabrutinib and ONO/GS-4059). This review discusses recent studies that may explain this apparent paradox and gives mechanistic insights that suggest a unique potential of low dose irreversible Btk inhibitors as atherothrombosis-focused antiplatelet drugs. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1055/s-0039-1687877 |
| الاتاحة: | https://cris.maastrichtuniversity.nl/en/publications/13352cac-75cf-4892-b996-1c7e5f2c817f https://doi.org/10.1055/s-0039-1687877 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.7D09B9B7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1055/s-0039-1687877 |
|---|